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Summary
Chronic hepatitis C virus (HCV) infection has been associated with both organ-specific and systemic autoimmune diseases, 
with cryoglobulinemia being the most frequent associated disease. Experimental, virologic, and clinical evidence have demon-
strated a close association between HCV infection and some systemic autoimmune diseases, especially Sjögren’s syndrome, but 
also rheumatoid arthritis and lupus. A higher prevalence of hematological processes has also been described in patients with 
HCV infection, including cytopenias and lymphoproliferative disorders (B-cell lymphoma). In addition, patients with chronic 
HCV infection have a higher frequency of other extrahepatic manifestations including endocrine, metabolic and cardiovascular 
disorders that may worse the prognosis of patients, along with neuropsychiatric manifestations and general symptoms that have 
a significant influence on the quality of life of the patient. Direct-acting antiviral therapies (DAAs) that have recently begun to 
be used are providing the opportunity to effectively cure chronic HCV infection and reduce the burden of both hepatic and 
extrahepatic complications.
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1. INTrODuCTION
Hepatitis C virus (HCV) was first isolated from 
an infected chimpanzee in 1988. It is a single-stranded 
RNA virus enveloped in a lipid bilayer belonging to 
the Flaviviridae family and more specifically to one 
of its three genera: hepacivirus. Its genome includes 
over 9400 nucleotides and several regions. HCV is 
one of the virus with a greatest genome variability. Its 
genome heterogeneity is one of the main features of 
HCV, which can be classified as follows: genotypes, 
subtypes and quasispecies. The underlying reason of 
such variability is a lack of the corrective activity of 
virus-dependent RNA-polymerase leading to the fre-
quent introduction of nucleotide substitutions in the 
virus genome. Within the same genotype, sequences 
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are homologous in around 95%, while between gen-
otypes they are so in only 65% of cases. Continuous 
mutation of HCV significantly threatens the immune 
memory since the number of memory cells originat-
ing from the first exposure capable of recognizing the 
new varieties are less and less with each new mutation. 
1
Autoimmunity and viral infections are closely 
related, and viruses have been acknowledged as po-
tential etiologic or triggering agents for this kind of 
diseases (AID). For over twenty years, several au-
thors described the relationship between HCV and 
a heterogeneous array of extrahepatic manifestations 
such as pulmonary fibrosis, cutaneous vasculitis, glo-
merulonephritis, Mooren’s ulcer, porphyria cutanea 
tarda or lichen planus. Currently though, it has been 
accepted that for some of this entities, a direct link is 
difficult to establish. 2
Recently, a higher prevalence of endocrine –met-
abolic, cardiovascular and neuropsychiatric diseases 
has been described among HCV patients. Endo-
crine-metabolic alterations which are most frequently 
found are affection of the thyroid gland, gonadal dys-
function and insulin resistance/type 2 diabetes melli-
tus. Chronic infection by HCV has been described as 
an independent factor for cardiovascular events such 
as carotid atherosclerosis, myocardial infarction and 
heart failure, all of which are associated with poor 
outcomes. On the other hand, the presence of neu-
rological and psychiatric symptoms has been directly 
and indirectly associated with HCV. 
The relevance of chronic infection by HCV 
among the imprisoned population is clearly estab-
lished by its prevalence: up to 20 times higher than 
in the general population. This epidemiological data 
together with the special features of this population 
(risk factors, age, HIV coinfection, etc.) implies a 
complex situation affecting the common distribu-
tion of genotypes or the reinfection rate and thus, the 
therapeutic approach. 3-5 In this context, it is crucial 
to know what extrahepatic manifestations can imply 
underlying infection by HCV. In this review, we will 
go through the main extrahepatic manifestations that 
can contribute to an early diagnosis of HCV in this 
population. 
2.  ETIOPaTHOGENESIS OF EXTraHE-
PaTIC maNIFESTaTIONS
Obviously, the ultimate consequence of HCV in-
fection (healing vs. chronification) depends upon the 
integrity of the host’s immune system and the virus’s 
features at the time of infection. In most cases, the virus 
overcomes the immune system and it “settles” within 
cells, where it remains isolated from the immune sys-
tem (Table 1). It is possible that plasmatic lipoprotein 
binding and the existence of quasispecies are involved 
in this first escape from the immune system. The infec-
tion or chronic presentation of viral antigens to lym-
phocytes entails their monoclonal expansion therefore 
implying the presence of circulating cryoglobulins. 
The risk for developing cryoglobulinemia increas-
es with the duration of HCV infection and thus, the 
presence of those cryoglobulins may finally produce 
vasculitis symptoms. Potentially, (infected) B lympho-
cyte proliferation could become uncontrollable, there-
fore inducing the development of lymphoma. Anyway, 
lymphoproliferation and its evolution from a benign 
form to a malign presentation is most probably a pro-
cess with multiple stages where one or more infectious 
agents could play a determining role, as well as genetic 
and environmental factors. 6
Table 1: Extrahepatic localication of Hepatitis C Virus infection.
a) Extrahepatic tissues Referencias
Salivary glands
Arrieta et al. (2001),  
Toussirot et al. (2002)
Gastric mucosa De Vita et al. (2000)
Striated muscle
Authier et al. (2003),  
Di Muzio et al. (2003)
Peripheral nerve
Authier et al. (2003),  
Bonetti et al. (1999)
Central nervous system Radkowski et al. (2002)
Myocardium Okabe et al. (1997)
Skin Agnello and Abel (1997)
b) Blood cells Referencias
B-Lymphocytes
Crovatto et al. (2000),  
Ducoulombier et al. (2004)
T-Lymphocytes Crovatto et al. (2000)
Monocytes Crovatto et al. (2000)
Neutrophils Crovatto et al. (2000)
Platelets Crovatto et al. (2000)
Patients with chronic HCV infection frequently 
present autoimmune phenomena with extremely vari-
able clinical relevance: from subclinical alterations to 
very severe immunological alterations (Table 2). On 
the other hand, autoimmune manifestations associ-
ated to chronic HCV infection can eventually be the 
reason why HCV infection is diagnosed, due to the 
lack of specific clinical or biological manifestations of 
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chronic HCV infection, with the existence of viremia 
in the absence of hepatic affectation. 
3. auTOImmuNE maNIFESTaTIONS
3. 1. Systemic autoimmune diseases
The association between systemic autoimmune 
diseases hand chronic HCV infection has arisen great 
interest for the last few years. 7 Extrahepatic manifes-
tations frequently found among patients with chronic 
HCV infection (both clinical and immunological) can 
lead to the fulfilling of current criteria for some sys-
tem autoimmune diseases (Table 3). 
The clinical association of different SADs with 
chronic HCV infection can be analyzed from two dif-
ferent yet complementary points of view. First, a revi-
sion of literature concluded that around 500 patients 
with SADs coexisted with chronic HCV infection 5, 
Sjögren’s syndrome (SS), rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE) and polyarteri-
tis nodosa (PAN) being the most frequently found. 
1 Next, the analysis of all series references of patients 
with SAD who underwent HCV testing showed a 
higher prevalence of HCV among patients with SS 
(17%), PAN (14.4%), SLE (9.6%) and RA (5.9%). 1 
More recent studies have focused on the association 
between HCV chronic infection and circulating au-
toantibodies, organ-specific autoimmune diseases and 
lymphoproliferative disorders. 
The largest study was published in 2009 by HIS-
PAMEC International Study Group. 8, 9 The HISPA-
MEC Registry is a multi-center international study 
group dedicated to data collection on systemic auto-
immune diseases co-existing with chronic HCV in-
fection. The study included 1020 patients with chron-
ic HCV infection and co-existing SAD in Southern 
Europe (60%), North America (15%), Asia (14%), 
Northern Europe (9%), South America (1%) and 
Australia (1%). SAD most frequently described were 
SS (483 cases), RA (150 cases), SLE (129 cases), PAN 
(78 cases), antiphospholipid syndrome (APS) (59 cas-
es), inflammatory myopathy (39 cases) and sarcoid-
osis (28 cases). Therefore, most frequently SAD as-
sociated with chronic HCV infection were SS (almost 
half of the cases), RA and SLE with almost two thirds 
of the cases reported in the Mediterranean area. In pa-
tients with coexisting SAD and HCV infection, the 
predominant immunological features were the pres-
ence of ANA, RF and cryoglobulins. 
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Table 2. Organ-specific manifestations of HCV patients with extrahepatic manifestations according to severity. 
a) mild and moderate manifestations
—  Purpura
—  Sporadic cutaneous ulceration
—  Arthralgia/Arthritis
—  Non-inflammatory muscle pain
—  General conditions (malaise, fever)
—  Mild to moderate neuropathy (sensitive)
b) Severe manifestations 
—  Persisting, multiple cutaneous ulceration that does not heal
—  Finger ischemia
—  Severe neuropathy (Motor or motor-sensitive)
—  Glomerulonephritis with / without renal disease / nephrotic syndrome
—  Interstitial lung disease
—  vascular gastrointestinal affectation (non-necrotizing)
—  severe autoimmune cytopenias (symptomatic hemolytic anemia / thrombocytopenia)
c) potentially fatal manifestations
—  Rapidly progressive glomerulonephritis
—  CNS affectation
—  Acute Necrotizing intestinal vasculitis 
—  Alveolar hemorrhage
—  Coronary artery disase (other etiology excluded)
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3.1.1. Vasculitis autoimmune manifestations
Cryoglobulinemia is the autoimmune manifes- 
tation most frequently described among HCV pa-
tients. Mixed cryoglobulins are identified in between 
40 and 60% of patients with chronic HCV infection 
although cryoglobulinemic vasculitis in only observed 
in around 10% 10. The main clinical manifestations 
include purpura, arthralgia, weakness, myalgia, poly-
neuropathy, glomerulonephritis and intestinal isch-
emia. Patients with cryoglobulinemia present a broad 
range of clinical features. 10 Although 50% of patients 
present a relatively benign evolution with good prog-
nosis and survival, some patients can present a severe 
affectation of internal organs. 11, 12 Two studies have 
assessed the clinical features of cryoglobulinemia as-
sociated with HCV in large series of patients. Sene 
et al. 13 retrospectively evaluated 123 patients with 
mixed cryoglobulinemia (MC) and concluded that 
cryoglobulinemic vasculitis was associated with older 
age, longer duration of HCV infection, MC type II 
and high levels of serum cryoglobulins. Ferri et al. 12 
analyzed demographical, clinical and serological fea-
tures and the survival of 231 patients with MC. One 
hundred and sixty eight patients were tested for HCV 
infection, which proved positive in 155 (92%). Ma-
lignant neoplasms were observed in 15% of patients 
mainly non-Hodgkin lymphoma (NHL) and hepato-
cellular carcinoma and the main causes of death were 
associated with MC (64%), NHL (13%) and hepatic 
failure (13%). 
The reason why some patients present severe 
forms of vasculitis (cryoglobulinemic) remains an 
open question. Ferri et al. 12 described that 35% of 
their patients with cryoglobulinemic patients had a 
moderate to severe clinical course and the prognosis 
was determined by both the cryoglobulinemic affec-
tation and HCV-associated conditions such as hepatic 
failure.  Cryoglobulinemia can be life threatening for 
HCV-patients in about 10-15% of cases. The presence 
of renal, intestinal, heart or CNS affectation entail 
a poor prognosis. Actually, recent data suggest that 
cryoglobulinemic glomerulonephritis significantly af-
fects both prognosis and survival. 10 Around 30% of 
patients can develop moderate to severe forms of the 
disease and almost 15% can be potentially fatal. 10
Alike other virus-associated vasculitis (HBV, 
HIV), the activity of HCV-associated cryoglobulin-
emic vasculitis generally correlates with viremia 14. 
Treatment should focus on potential causal agents. 
Therefore, antivirals are the cornerstone of therapies 
against this type of vasculitis. Currently, direct-act-
ing antivirals (DAA) have provided higher rates of 
sustained virologic response (SVR) and lower burden 
of toxicity for HCV patients and more recently, the 
first significant series of patients with HCV-associat-
ed cryoglobulinemic vasculitis effectively treated with 
DAA have been published. 14, 15
3.1.2 Non vasculitic autoimmune manifestations
a) Sjögren’s syndrome. Several experimental stud-
ies both virologic and clinical support a close rela-
tionship between HCV and SS. In 2002, the HCV-SS 
Study Group was formed, a multicenter internation-
al collaboration group which identified 137 patients 
with HCV and SS.  2 They determined that HCV-as-
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Table 3. Different degrees of association between HCV infection and systemic autoimmune diseases 
Degree of association Extrahepatic manifestations with overlap of classifcation criteria 
HIGH CRITERIA
Sjögren’s Syndrome Dry mouth, dry eyes, positive eye tests, positive salivary gland biopsy, ANA, RF 
Rheumatoid arthritis Arthritis in three or more joints, arthritis in the hand, symmetric arthritis, RF 
Systemic lupus erythematosus Joint involvement, renal involvement, ANA, aPL, cytopenia 
INTERMEDIATE
Polyartheritis nodosa Debilidad, neuropatía periférica, creatinina elevada, marcadores positivos de VHB
Antiphospholipid syndrome Positive APL , atypical thrombotic events
Sarcoidosis Pulmonary fibrosis
Inflammatory myopathies Muscle weakness. Elevation of GOT, GPT 
LOW
Systemic sclerosis Pulmonary fibrosis
Wegener granulomatosis Renal involvement
Giant cell arteritis Age over 50
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sociated SS is indistinguishable from the primary 
form in most cases according to the most recent clas-
sification criteria and the term HCV-associated SS 
was proposed for all HCV patients fulfilling SS 2002 
classification criteria. 2 HCV chronic infection should 
be considered an exclusion criterion for primary SS 
because the virus could be involved in the develop-
ment of SS in a particular sub-group of patients, not 
due to the similarity of both forms. 2 Nevertheless, 
there is no conclusive evidence on the beneficial effect 
of antivirals for these patients. 
b) Joint involvement and rheumatoid arthritis. 
Joint involvement in the form of arthralgia and ar-
thritis is one of the extrahepatic manifestations most 
frequently reported. It is reasonable to therefore 
consider, that HCV patients with polyarthritis and 
positive RF suffer from some type of RA. HACV 
patients can present four of the 1998 ACR revised 
criteria: involvement of three or more joints, arthritis 
of the hand, symmetric arthritis and RF. Rosner and 
col. 16 revised thoroughly the prevalence and clinical 
features of HCV-associated arthritis and assessed the 
significant coincidence with RA. The most common 
presentation of HCV-associated arthritis is chron-
ic inflammatory polyarthritis, which fulfills ACR 
classification criteria in over 50% of cases. The pres-
ence of morning stiffness, rheumatoid nodules and 
erosive arthritis (rarely reported in HCV infection) 
can be useful in diagnosing actual coexistence of RA 
and HCV. Patel et al. 17 identified 92 HCV + patients 
(5.1%) out of 1706 patients with RA. In comparison 
with AR patients negative for HCV, HCV positive 
patients were younger, predominantly Afro-Ameri-
can and smokers. Authors also concluded that RA pa-
tients with chronic HCV infection had higher scores 
for the activity of the disease (mainly associated with 
higher means reported by patients) and a higher prob-
ability of undergoing treatment with prednisone and 
anti-TNF alpha therapies and less likely to be treated 
with methotrexate than HCV negative patients. Re-
cent studies have confirmed that anti-CCP antibod-
ies can be useful in differentiating patients with HCV 
and a real RA from those with HCV-associated ar-
thropathy. Ezzaz et al. 18 evaluated 30 patients with 
RA and 22 patients with HCV-associated polyar-
thritis and concluded that 83% of patients with RA 
presented anti-CCP antibodies while only 4.5% of 
HCV-associated polyarthopathy did. The determina-
tion of anti-CCP antibodies proved more specific for 
the diagnosis of RA than RF (95.4 vs. 18.2%) while 
sensitivity was similar (83.3 vs. 90%). 
c) Lupus-related manifestations. Virus have been 
proposed as potential etiologic agents or triggering 
factors for SLE. HCV chronic infection can induce 
clinical and serological features (arthritis, nephropa-
thy, cytopenia and low levels of ANA or anti-DNA) 
which, together, can fulfill 1982 ACR criteria for 
SLE. In this regard, some studies have suggested that 
HCV can fake SLE. Several authors have analyzed 
the prevalence of HCV infection in SLE patients and 
some case reports have been published on this topic. 19 
Ramos-Casals et al. 20 analyzed a large series of SLE 
patients and concluded that HCV was present in 11% 
of an unselected SLE population. This prevalence is 
significantly higher than that found in the control 
group (1%) and in the general population of Catal-
onia (1.2%). This suggests a potential link between 
HCV infection and SLE. Similar results have been 
obtained by Ahmed et al. 21 in USA (10% in SLE 
patients in comparison with 1.3% among the general 
population). 
d) Pulmonary involvement and sarcoidosis. The 
first association between sarcoidosis and HCV was 
described in 1993 strictly related with the initiation 
of interferon-alpha treatment. Ramos-Casals et al. 22 
analyzed clinical features and results of 68 cases of 
sarcoidosis coexisting with chronic HCV infection, 
in 75% of which sarcoidosis was triggered by antivi-
ral therapy. 22 Other patterns of association between 
sarcoidosis and HCV have been described: 1) The co-
existence of both diseases in patients with HCV infec-
tion with no prior treatment and 2) the reactivation of 
preexisting sarcoidosis in HCV patients later treated 
with anti-HCV agents. The association with idiopath-
ic pulmonary fibrosis and other forms of interstitial 
lung disease (ILD) have also been described. 
e) Muscle involvement and inflammatory myopa-
thy. The presence of muscle pain (myalgia) in patients 
with chronic HCV infection is very common, yet 
the diagnosis of inflammatory myopathy is rare. The 
association between these entities is mostly in isolat-
ed cases, with a total of 36 published reports out of 
which 21 were polymyositis. 23 On the other hand, 
only three studies have assessed the prevalence of 
HCV in series of patients with inflammatory myop-
athy and HCV infection was present in twelve out of 
126 patients (9.5%). 23 Bohan and Peter criteria show 
a slight degree of overlap with HCV infection since 
HCV patients rarely present muscle weakness with 
elevated levels of muscle enzymes or electromyo-
graphic evidence of generalized myopathy. Therefore, 
currently, inflammatory myopathy is weakly associ-
ated with HCV infection. A recent case-control study 
24 have analyzed the prevalence of HCV infection 
in 114 patients with inclusion body myositis and 44 
patients with polymyositis aged similarly in the same 
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period of time. A higher frequency of HCV infection 
was found among patients with inclusion body myo-
sitis than in those with polymyositis and the general 
Japanese population (28% vs. 4.5% vs. 3.4%) suggest-
ing a plausible etiopathogenic link between HCV and 
inclusion body myositis. 
 3.2. Organ-specific autoimmune diseases
Autoimmune thyroiditis is the organ-specific au-
toimmune disease most frequently associated with 
chronic HCV infection. The role of HCV in the in-
duction of thyroid autoimmunity remains unclear. 
Bini and Mehandru 25 described the development of 
thyroid disease (both evident and subclinical) in 11% 
of two hundred and twenty-five male patients with 
HCV infection and combined antiviral therapy al-
though the thyroid disease responded to specific treat-
ment and was reversible in most cases. Antonelli et 
al. 26 described a higher frequency of hypothyroidism 
(13%) and anti-thyroid antibodies (21%) in 630 pa-
tients with HCV infection and no treatment in com-
parison with normal controls and found similar re-
sults in a sub-group of patients with associated mixed 
cryoglobulinemia. However, other studies carried out 
in the same geographical area did not conclude this 
close association. Floreani et al. 27 tested six hundred 
and ninety-seven Italian patients for thyroid autoan-
tibodies and anti-HCV antibodies. Out of 71 HCV 
positive patients, four (6%) were positive for at least 
one thyroid antibody, compared with seven (5%) of 
negative controls according to age and gender. 
4.  HEmaTOLOGIC DISOrDErS
The specific tropism of HCV for many types of 
extrahepatic cells (Table 1), especially for blood cells 
has been suggested by many studies, therefore estab-
lishing a clear bond between HCV and the develop-
ment of autoimmune and proliferative disorders. 
4.1. Cytopenia
Although HCV-associated cytopenia is not un-
common, in general terms it is considered a mild alter-
ation with no clinical relevance, especially in patients 
with hypersplenism. Thrombocytopenia is the most 
common, with a chronic course and rarely entailing 
severe bleeding.  Severe cytopenia is present in some 
HCV patients, regardless of antiviral therapy. Throm-
bocytopenia can be severe (under 30x 109/L) in HCV 
patients with no prior treatment and in some cases it is 
associated with concomitant autoimmune disorders, 
with cryoglobulinemia and with simultaneous HIV 
infection. Recently, two cases of autoimmune hemo-
lytic anemia (AHA) with positive Coombs test in 
patients with no IFN treatment have been reported. 
Previously seventeen cases of AHA associated with 
HCV infection had been described, mostly associated 
with autoimmune disorders, among which cryoglob-
ulinemia was the most common. 
4.2. Lymphoma
Several studies have concluded a higher prevalence 
of lymphoproliferative disorders among HCV pa-
tients. 28 Matsuo et al. 29 and Iwata et al. 30 carried out a 
meta-analysis of twenty-three epidemiological studies 
on the association between HCV and NHL, includ-
ing 4049 patients with NHL. Odds-ration (OR) for 
NHL in HCV patients was 5.70; 5.04 for B-cell NHL 
and 2.51 for T-cell NHL. 29 Dal Maso and Frances-
chi 31 carried out a similar meta-analysis to determine 
the strength and accuracy of the association between 
HCV and NHL, including only Z100 studies accord-
ing to age and gender. Combined RR of all NHL in 
HCV patients was 2.5. Nieters et al. 32 studied the 
presence of HCV infection in samples form 1807 cas-
es of NHL and 1788 controls and found HCV in 53 
(2.9%) of lymphoma cases and in 41 (2.3%) of con-
trols (OR 1.42). When limited to patients with positive 
HCV RNA, OR raised to 1.82. The most frequent case 
of lymphoma in HCV patients is B-cell lymphoma or 
NHL and marginal zone lymphoma the most common 
subtype. IN most cases, there is an excellent response 
to treatment after receiving antiviral therapy 7. 
5.  ENDOCrINE. mETaBOLIC  
aFFECTaTION
5.1. Diabetes mellitus
Several clinical studies have suggested a potential 
link between chronic hepatitis caused by HCV and 
the development of diabetes mellitus (DM). Antonelli 
et al. 33 described that the prevalence of type 2 DM is 
higher in HCV- MC patients. Diabetic patients with 
HCV infection and MC have also a more pronounced 
autoimmune reactivity than non-HCV diabetic pa-
tients. The development of hepatic fibrosis has been 
associated with insulin resistance in patients with 
chronic HCV infection 31 and DM can contribute to 
the presence and severity of hepatic encephalopathy 
regardless of the severity of the hepatic disorder. A 
recent meta-analysis describes that concomitant DM 
is associated with a higher risk of hepatocellular carci-
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noma, in association with body mass index (BMI) and 
steatosis 34, while Hwang et al. 35 have described that 
chronic HCV infection increases the risk for develop-
ing end-stage renal disease in patients with DM. 
5.2. Hepatic steatosis
Metabolic disorders in HCV patients can be as-
sociated to the development of hepatic steatosis, with 
a clinical relevance which has been recently empha-
sized. There are several factors associated with hepat-
ic steatosis including obesity, use of alcohol, type 2 
DM and hyperlipidemia. The infection by genotype 3 
is particularly associated with fatty deposition in the 
liver.  Leandro et al. 36 carried out a meta-analysis in 
3068 patients with histologically confirmed chronic 
HCV infection. Steatosis was present in 1561 patients 
(51%) and fibrosis in 2688 (88%). Steatosis was inde-
pendently associated with genotype 3, fibrosis, dia-
betes, hepatic inflammation, alcohol use, higher BMI 
and older age. Antiviral therapy and cure of the infec-
tion is associated with the disappearance of steatosis, 
especially in patients with genotype 3 infection, with 
no other risk factors. In patients with persisting ste-
atosis, the control of metabolic factors such as over-
weight and the modification of lifestyle seem import-
ant in the management of chronic HCV infection.  
6.  aTHErOmaTOSIS aND  
CarDIOVaSCuLar maNIFESTaTIONS
There is a higher risk for the development of car-
diovascular disorders in patients with chronic HCV 
infection 7. This infection is a proven independent risk 
factor for the development of cardiovascular manifes-
tations such as carotid atherosclerosis, heart failure 
and stroke. It has all been attributed with a higher 
cardiovascular mortality throughout the course of 
chronic HCV infection and thus, with a relevant im-
pact in the prognosis of the patient. Chronic HCV 
infection can be reasonably considered as potential-
ly iatrogenic since it promotes insulin resistance and 
type 2 diabetes, and due to the replication of HCV 
within carotid plaques 7. 
7.  NEurOPHySCHIaTrIC maNIFESTa-
TIONS aND GENEraL SymPTOmS
Neuropsychiatric manifestations are included 
in the array of extrahepatic manifestations of HCV 
infection. Their etiopathogenesis is complex and 
can include several mechanisms such as direct neu-
ro-invasion, immunologically mediated lesion due 
to antibodies against antigens in the nervous tissue 
or ischemic alterations secondary to vasculitis/ath-
eromatosis. Up to 50% of patients with HCV infec-
tion can develop a variable combination of clinical or 
subclinical neuropsychiatric manifestations including 
peripheral polyneuropathy, CNS manifestations (en-
cephalopathy, myelitis, vascular events) and neuro-
psychological/psychiatric manifestations 7. 
Neuropsychiatric symptoms have been directly 
related with an important affectation of the quality 
of life of patients together with other symptoms such 
as sexual dysfunction and depression, chronic fatigue, 
chronic joint and muscle pain and fibromyalgia. The 
treatment of chronic HCV infection including inter-
feron can further jeopardize patients’ quality of life 
since some of its adverse effects include fatigue, mus-
cle pain, depression and cognitive impairment. New 
agents, with different adverse effects profiles and dif-
ferent regimens can allow patients to achieve SVR and 
preserve their quality of life. 
8. THEraPEuTIC ImPLICaTIONS
Currently there are no international recommen-
dations on the treatment of HCV patients with extra-
hepatic manifestations (EHM). The first approaches 
are based on immunosuppressive therapies such as 
those used in non-HCV vasculitis. The introduction 
of the first combination of antiviral agents (interferon 
and ribavirin) clearly improved survival rates. Nev-
ertheless, this approach had a poor virologic efficacy 
(eradication under 50% for genotype 1 HCV) and of-
ten included several months and high rates of intoler-
ance. 37 Direct-acting antivirals (DAA) have been re-
cently introduced as an effective alternative for HCV 
infection, with short duration of treatment, minimum 
adverse effects and an efficacy close to 100%. 38 These 
new agents are allowing an efficient cure for HCV in-
fection with a reduced burden due to hepatic and ex-
trahepatic complications, therefore providing the op-
portunity of a dramatic change in the results of these 
patients. The objective of a recently published mul-
tidisciplinary international consensus 39 is to provide 
the first set of evidence-based recommendations on a 
homogenous therapeutic approach for HCV patients 
with extrahepatic manifestations in the new DAA era 
(Tables 4 and 5). 
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Table 4. Evaluation of therapeutic response: results mainly used in published studies on patients with EHM.  
a) Clinical response
By clinicians, often classified as:
—  complete: all symptoms/organs involved achieved complete response 
—  partial response: incomplete organ-response or no all organs responded
—  without response: stabilization, worsening
b) Immunological response
—  reduction of serum levels of cryoglobulins
—  high levels of C4
—  elimination/reduction of levels of RF
c) Virologic response
—  SVR 12 weeks after treatment
Tabla 5. Recommendations for the treatment of extrahepatic manifestations 39
—  Antiviral therapy is recommended in all patients with EHM except for those with limited life expectancy 
due to other causes. 
—  Regimens base don DAA, without IFN (with or without ribavirin) should be considered the gold standard 
approach for patients with EHM.
—  Patients with EHM should be treated according to the DAA international recommendations for mono-
infected patients.
—  Health service providers and clinicians, when considering different DAA regimens with similar SVR rates 
should consider both the return and the impact of adverse effects associated with the selected regimen. 
—  In case of limited resources, patients with a more severe condition should be treated first. 
—  Autoimmune diseases classification criteria should be confirmed, or a clinical conclusive evidence should 
be available when diagnosing EHM after discarding other etiologies. 
9. CONCLuSIONS
Obviously, HCV infection should be approached 
from a systemic point of view due to the strong asso-
ciation with different types of extrahepatic manifes-
tations, of autoimmune, hematological or metabolic 
origin (Figure 1). Clinical extrahepatic manifestations 
can be observed in several localizations the most 
frequent being: joint involvement (arthralgia and/
or arthritis), skin conditions (purpura), neurologi-
cal disorders (polyneuropathy), renal manifestations 
(glomerulonephritis), pulmonary disorders (alveo-
litis), thyroid (thyroiditis), eye and mucosae affec-
tation (dryness) and soft tissue manifestations (fi-
bromyalgia). Currently, available data underline the 
importance of a new approach on the prevalence of 
so-considered “extrahepatic manifestations” due to 
large series of patients and the use of specific tech-
niques. Therefore, we could consider the follow-
ing “common” extrahepatic manifestations (with a 
prevalence ranging between 10 and 20%): arthralgia, 
mucous dryness and fibromyalgia and “relatively 
common” (5-10%) cutaneous vasculitis, polyneurop-
athy and glomerulonephritis (directly related with 
cryoglobulinemia). Finally, there are three manifes-
tations classically considered as HCV-associated and 
whose relationship has not been established in the 
later publications: Thyroid manifestations (associat-
ed with interferon therapies and some age groups), 
pulmonary fibrosis and Mooren corneal ulcers. 
Finally, it is worth considering that the appearance 
of extrahepatic manifestations and positive immuno-
logical results can lead to the diagnosis of a specific 
system autoimmune disorder, according to the corre-
sponding criteria. Research throughout the last thirty 
years on HCV points to two clear facts. The first is 
that cryoglobulinemia is associated with many of the 
autoimmune manifestations (both clinical and sero-
logical) in HCV patients and that cryoglobulinemic 
syndrome seems to be the great simulator of system-
ic autoimmune disease. The second is that there are 
certain autoimmune diseases such as SLE, DD or RA 
that are frequently found among patients with chron-
ic HCV infection. 
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